Russell Bradley, President and General Manager of CNSide Diagnostics, was recently featured in an interview with InnovationMap, where he discussed the company’s CNSide® Cerebrospinal Fluid (CSF) Assay Platform — an advanced diagnostic designed to help clinicians detect cancers that metastasize to the brain and spine earlier, providing more treatment options for patients with leptomeningeal metastases (LM).

The CNSide® CSF Assay represents a breakthrough in precision oncology diagnostics by offering highly sensitive detection of tumor cells in cerebrospinal fluid. This technology enables earlier insights into disease progression, allowing clinicians to make more informed treatment decisions for patients with complex central nervous system (CNS) cancers.

“Our mission is to transform how clinicians detect and monitor cancers that spread to the brain and spine,” said Russell Bradley, President & GM of CNSide Diagnostics. “By providing earlier, actionable insights, the CNSide® platform has the potential to change care pathways and improve outcomes for patients with leptomeningeal metastases.”

Why This Matters for Patients & Providers

• Earlier Detection: Identifies cancer cells in the cerebrospinal fluid with high sensitivity, supporting timely diagnosis.
• Real-Time Monitoring: Tracks disease progression and treatment response to inform personalized therapy.
• Improved Patient Options: Empowers clinicians with data that can open more treatment pathways for patients with LM and other CNS cancers.

This InnovationMap feature underscores the growing impact of CNSide Diagnostics in advancing precision medicine and neuro-oncology care.

Read the Full Interview & Stay Connected

Read the full InnovationMap story: Click Here
Learn more about CNSide® Diagnostics: CNSide Official Website
Join our interest list to stay updated: Sign Up Here

#CNSideDiagnostics #Oncology #Diagnostics #LMD #LeptomeningealMetastases #PrecisionDiagnostics #CNSCancer #NeuroOncology #HealthcareInnovation #CancerDetection